Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Table of Contents

May 1, 2022; Volume 63,Issue 5

This Month in JNM

  • You have access
    This Month in JNM
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 10A;

Discussions with Leaders

  • You have access
    Translational Cancer Research Priorities and the Role of Molecular Imaging
    Chi Van Dang, Elizabeth Jaffee and David Mankoff
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 637-639; DOI: https://doi.org/10.2967/jnumed.122.264086

The State of The Art

  • Open Access
    A Guideline for Clinicians Performing Clinical Studies with Fluorescence Imaging
    Wido Heeman, Jasper Vonk, Vasilis Ntziachristos, Brian W. Pogue, Rudi A.J.O. Dierckx, Schelto Kruijff and Gooitzen M. van Dam
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 640-645; DOI: https://doi.org/10.2967/jnumed.121.262975

Hot Topics

  • Open Access
    Total-Body PET: Will It Change Science and Practice?
    Austin R. Pantel, David A. Mankoff and Joel S. Karp
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 646-648; DOI: https://doi.org/10.2967/jnumed.121.263481

Continuing Education

  • You have access
    Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 1: Technical Considerations and Perfusion and Neuronal Imaging
    John C. Stendahl, Jennifer M. Kwan, Darko Pucar and Mehran M. Sadeghi
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 649-658; DOI: https://doi.org/10.2967/jnumed.121.263506

Focus on Molecular Imaging

  • You have access
    Signaling Pathways That Drive 18F-FDG Accumulation in Cancer
    Jessica R. Salas and Peter M. Clark
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 659-663; DOI: https://doi.org/10.2967/jnumed.121.262609

Oncology

  • Clinical

    • 
    <sup>11</sup>C-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence
      You have access
      11C-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence
      Asim K. Bag, Melissa N. Wing, Noah D. Sabin, Scott N. Hwang, Gregory T. Armstrong, Yuanyuan Han, Yimei Li, Scott E. Snyder, Giles W. Robinson, Ibrahim Qaddoumi, Alberto Broniscer, John T. Lucas and Barry L. Shulkin
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 664-671; DOI: https://doi.org/10.2967/jnumed.120.261891
    • Epidermal Growth Factor Receptor–Targeted Fluorescence Molecular Imaging for Postoperative Lymph Node Assessment in Patients with Oral Cancer
      Open Access
      Epidermal Growth Factor Receptor–Targeted Fluorescence Molecular Imaging for Postoperative Lymph Node Assessment in Patients with Oral Cancer
      Jasper Vonk, Jaron G. de Wit, Floris J. Voskuil, Yang Hang Tang, Wouter T.R. Hooghiemstra, Matthijs D. Linssen, Evert van den Broek, Jan J. Doff, Sebastiaan A.H.J. de Visscher, Kees-Pieter Schepman, Bert van der Vegt, Gooitzen M. van Dam and Max J.H. Witjes
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 672-678; DOI: https://doi.org/10.2967/jnumed.121.262530
    • 
    <sup>90</sup>Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study
      You have access
      90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study
      Benedikt M. Schaarschmidt, Moritz Wildgruber, Roman Kloeckner, James Nie, Verena Steinle, Arthur J.A.T. Braat, Fabian Lohoefer, Hyun S. Kim, Harald Lahner, Manuel Weber and Jens Theysohn
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 679-685; DOI: https://doi.org/10.2967/jnumed.121.262561
    • PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
      You have access
      PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
      Jasper Smit, Frank J. Borm, Anna-Larissa N. Niemeijer, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Daniela E. Oprea-Lager, Danielle J. Vugts, Guus A.M.S. van Dongen, Berlinda J. de Wit-van der Veen, Erik Thunnissen, Egbert F. Smit and Adrianus J. de Langen
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 686-693; DOI: https://doi.org/10.2967/jnumed.121.262473
    • 
    Biodistribution of <sup>18</sup>F-FES in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant (G1T48), a Novel Selective ER Degrader
      You have access
      Biodistribution of 18F-FES in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant (G1T48), a Novel Selective ER Degrader
      Ramsha Iqbal, Maqsood Yaqub, Daniela E. Oprea-Lager, Yeukman Liu, Anne Marije Luik, Andy P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard and Catharina W. Menke-van der Houven van Oordt
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 694-699; DOI: https://doi.org/10.2967/jnumed.121.262500
    • INVITED PERSPECTIVE

      • You have access
        ER Imaging for Estrogen-Related Tumors Is Bothersome but Useful
        Hidehiko Okazawa
        Journal of Nuclear Medicine May 1, 2022, 63 (5) 700-701; DOI: https://doi.org/10.2967/jnumed.121.263170
    • 
    <sup>18</sup>F-4FMFES and <sup>18</sup>F-FDG PET/CT in Estrogen Receptor–Positive Endometrial Carcinomas: Preliminary Report
      You have access
      18F-4FMFES and 18F-FDG PET/CT in Estrogen Receptor–Positive Endometrial Carcinomas: Preliminary Report
      Michel Paquette, Esteban Espinosa-Bentancourt, Éric Lavallée, Serge Phoenix, Korine Lapointe-Milot, Paul Bessette, Brigitte Guérin and Éric E. Turcotte
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 702-707; DOI: https://doi.org/10.2967/jnumed.121.262617
    • 
    <sup>18</sup>F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma
      You have access
      18F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma
      Joseph G. Crompton, Wesley R. Armstrong, Mark A. Eckardt, Ameen Seyedroudbari, William D. Tap, Sarah M. Dry, Evan R. Abt, Jeremie Calais, Ken Herrmann, Johannes Czernin, Fritz C. Eilber and Matthias R. Benz
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 708-712; DOI: https://doi.org/10.2967/jnumed.121.262502
    • 
    Detection of Additional Primary Neoplasms on <sup>18</sup>F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer
      You have access
      Detection of Additional Primary Neoplasms on 18F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer
      Ashwin Singh Parihar, Lisa R. Schmidt, Farrokh Dehdashti and Richard L. Wahl
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 713-719; DOI: https://doi.org/10.2967/jnumed.121.262647
    • FEATURED ARTICLE OF THE MONTH

      • CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
        You have access
        CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
        Michael D. Farwell, Raymond F. Gamache, Hasan Babazada, Matthew D. Hellmann, James J. Harding, Ron Korn, Alessandro Mascioni, William Le, Ian Wilson, Michael S. Gordon, Anna M. Wu, Gary A. Ulaner, Jedd D. Wolchok, Michael A. Postow and Neeta Pandit-Taskar
        Journal of Nuclear Medicine May 1, 2022, 63 (5) 720-726; DOI: https://doi.org/10.2967/jnumed.121.262485

Theranostics

  • Clinical

    • 
    Initial Clinical Experience with <sup>90</sup>Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
      You have access
      Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
      Justin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, Manuel Weber, Nader Hirmas, Karina Kostbade, Sebastian Bauer, Martin Schuler, Marit Ahrens, Hans-Ulrich Schildhaus, Christoph Rischpler, Hong Grafe, Jens T. Siveke, Ken Herrmann, Wolfgang P. Fendler and Rainer Hamacher
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 727-734; DOI: https://doi.org/10.2967/jnumed.121.262468
    • 
    A Comparison of <sup>18</sup>F-DCFPyL, <sup>18</sup>F-NaF, and <sup>18</sup>F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
      You have access
      A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer
      Aloÿse Fourquet, Adrian Rosenberg, Esther Mena, Joanna J. Shih, Baris Turkbey, Maxime Blain, Ethan Bergvall, Frank Lin, Stephen Adler, Ilhan Lim, Ravi A. Madan, Fatima Karzai, James L. Gulley, William L. Dahut, Bradford J. Wood, Richard Chang, Elliot Levy, Peter L. Choyke and Liza Lindenberg
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 735-741; DOI: https://doi.org/10.2967/jnumed.121.262371
    • BRIEF COMMUNICATION

      • 
    The Influence of Specific Activity on the Biodistribution of <sup>18</sup>F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data
        You have access
        The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data
        Thomas Langbein, Alexander Wurzer, Andrei Gafita, Andrew Robertson, Hui Wang, Ayça Arçay, Michael Herz, Hans-Juergen Wester, Wolfgang A. Weber and Matthias Eiber
        Journal of Nuclear Medicine May 1, 2022, 63 (5) 742-745; DOI: https://doi.org/10.2967/jnumed.121.262471
    • 
    Repeatability of <sup>68</sup>Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
      You have access
      Repeatability of 68Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
      Robert Seifert, Patrick Sandach, David Kersting, Wolfgang P. Fendler, Boris Hadaschik, Ken Herrmann, John J. Sunderland and Janet H. Pollard
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 746-753; DOI: https://doi.org/10.2967/jnumed.121.262528
    • 
    Biokinetics and Dosimetry of <sup>177</sup>Lu-Pentixather
      You have access
      Biokinetics and Dosimetry of 177Lu-Pentixather
      Heribert Hänscheid, Andreas Schirbel, Philipp Hartrampf, Sabrina Kraus, Rudolf A. Werner, Hermann Einsele, Hans-Jürgen Wester, Michael Lassmann, Martin Kortüm and Andreas K. Buck
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 754-760; DOI: https://doi.org/10.2967/jnumed.121.262295
  • Translational

    • Modeling Early Radiation DNA Damage Occurring During <sup>177</sup>Lu-DOTATATE Radionuclide Therapy
      Open Access
      Modeling Early Radiation DNA Damage Occurring During 177Lu-DOTATATE Radionuclide Therapy
      Giulia Tamborino, Yann Perrot, Marijke De Saint-Hubert, Lara Struelens, Julie Nonnekens, Marion De Jong, Mark W. Konijnenberg and Carmen Villagrasa
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 761-769; DOI: https://doi.org/10.2967/jnumed.121.262610

Cardiovascular

  • Clinical

    • Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial
      You have access
      Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial
      Senthil Selvaraj, Kenneth B. Margulies, Supritha Dugyala, Erin Schubert, Ann Tierney, Zoltan Arany, Daniel A. Pryma, Svati H. Shah, J. Eduardo Rame, Daniel P. Kelly and Paco E. Bravo
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 770-776; DOI: https://doi.org/10.2967/jnumed.121.262734

Neurology

  • Clinical

    • 
    Brain Stem Glucose Hypermetabolism in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia and Shortened Survival: An <sup>18</sup>F-FDG PET/MRI Study
      You have access
      Brain Stem Glucose Hypermetabolism in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia and Shortened Survival: An 18F-FDG PET/MRI Study
      Matteo Zanovello, Gianni Sorarù, Cristina Campi, Mariagiulia Anglani, Alessandro Spimpolo, Sara Berti, Cinzia Bussè, Stefano Mozzetta, Annachiara Cagnin and Diego Cecchin
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 777-784; DOI: https://doi.org/10.2967/jnumed.121.262232

Endocrinology

  • Clinical

    • 
    <sup>18</sup>F-Fluorocholine PET/CT Is More Sensitive Than <sup>11</sup>C-Methionine PET/CT for the Localization of Hyperfunctioning Parathyroid Tissue in Primary Hyperparathyroidism
      You have access
      18F-Fluorocholine PET/CT Is More Sensitive Than 11C-Methionine PET/CT for the Localization of Hyperfunctioning Parathyroid Tissue in Primary Hyperparathyroidism
      Céline Mathey, Caroline Keyzer, Didier Blocklet, Gaetan Van Simaeys, Nicola Trotta, Simon Lacroix, Bernard Corvilain, Serge Goldman and Rodrigo Moreno-Reyes
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 785-791; DOI: https://doi.org/10.2967/jnumed.121.262395
    • INVITED PERSPECTIVE

      • You have access
        Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes
        Hsiaoju Lee and Lisa J. States
        Journal of Nuclear Medicine May 1, 2022, 63 (5) 792-793; DOI: https://doi.org/10.2967/jnumed.121.263171
    • Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes
      You have access
      Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes
      Olof Eriksson, Irina Velikyan, Torsten Haack, Martin Bossart, Iina Laitinen, Philip J. Larsen, Jan Erik Berglund, Gunnar Antoni, Lars Johansson, Stefan Pierrou, Joachim Tillner and Michael Wagner
      Journal of Nuclear Medicine May 1, 2022, 63 (5) 794-800; DOI: https://doi.org/10.2967/jnumed.121.262506

Letters to the Editor

  • You have access
    18F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study
    Karl-Josef Langen and Felix M. Mottaghy
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 801; DOI: https://doi.org/10.2967/jnumed.122.263837
  • You have access
    Reply: 18F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study
    Timothée Zaragori and Antoine Verger
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 801-803; DOI: https://doi.org/10.2967/jnumed.122.264035
  • You have access
    Single–Time-Point Tumor Dosimetry Assuming Normal Distribution of Tumor Kinetics
    Yung Hsiang Kao
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 803; DOI: https://doi.org/10.2967/jnumed.121.263669
  • You have access
    Reply: Single–Time-Point Tumor Dosimetry Assuming Normal Distribution of Tumor Kinetics
    George Sgouros, Yuni K. Dewaraja, Freddy Escorcia, Stephen A. Graves, Thomas A. Hope, Amir Iravani, Neeta Pandit-Taskar, Babak Saboury, Sara St. James and Pat B. Zanzonico
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 804; DOI: https://doi.org/10.2967/jnumed.121.263717

SNMMI Newsline

  • You have access
    SNMMI Newsline
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 13N-24N;
  • You have access
    FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 13N;
  • You have access
    Updates to Appropriate Use Criteria for PSMA PET
    Thomas A. Hope and Hossein Jadvar
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 14N;
  • You have access
    ASNC/SNMMI Radionuclide Authorized User Training Course
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 15N;
  • You have access
    SNMMI Leadership Update: SNMMI’s Role in the Nuclear Medicine Renaissance
    Richard L. Wahl
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 16N-17N;
  • You have access
    Newsbriefs
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 18N-19N;
  • You have access
    From the Literature
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 20N-24N;
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 63 (5)
Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)

Issue highlights

  • CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
Sign up for alerts

Jump to

  • This Month in JNM
  • Discussions with Leaders
  • The State of The Art
  • Hot Topics
  • Continuing Education
  • Focus on Molecular Imaging
  • Oncology
    • Clinical
      • INVITED PERSPECTIVE
      • FEATURED ARTICLE OF THE MONTH
  • Theranostics
    • Clinical
      • BRIEF COMMUNICATION
    • Translational
  • Cardiovascular
    • Clinical
  • Neurology
    • Clinical
  • Endocrinology
    • Clinical
      • INVITED PERSPECTIVE
  • Letters to the Editor
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
  • Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
  • High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections
More...
SNMMI

© 2025 SNMMI

Powered by HighWire